Glenmark builds antibody expertise with Lay Line deal
This article was originally published in Scrip
Glenmark Pharmaceuticals has in-licensed the private Italian firm Lay Line Genomics' (LLG) intellectual property portfolio in the tyrosine kinase A (TrkA) field. The agreement includes LLG's BXL1H5, a monoclonal antibody that binds specifically to TrkA receptors.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.